Three–model D2 Series Debuts with AI–powered Local Storage and Versatile Smart Features
NEW YORK, July 3, 2025 /PRNewswire/ -- Global smart–home leader TCL today launches its all–new D2 Series Smart Locks, headlined by the flagship TCL D2 Pro Palm Vein Smart Lock. Building on the remarkable success of the first–generation D1 Pro in 2025—garnering multiple Best of CES honors and rave reviews from leading media outlets, and securing the #1 sales rank on Amazon for smart locks priced above $150—the D2 Pro raises the bar with industry–leading AI–driven palm vein recognition and 100% on–device data storage. Complemented by the D2 Plus and D2 models, the series addresses a wide range of budgets and use cases, bringing next–generation access control to households worldwide.
Key Features
AI–Driven Palm Vein Recognition
99.9999% accuracy (tested under controlled laboratory conditions), unaffected by moisture, dirt, or age, surpassing fingerprint and face–recognition solutions.
0.3–second unlock for instantaneous access, reliable in all lighting and weather conditions. Open like Iron Man with a simple wave.
100% Local Data Storage
Biometric templates and access logs reside solely on the device—no cloud transmission or remote dependency, eliminating hacker–targeted data leaks.
Flexible guest management with temporary PINs and shareable QR codes, plus tiered permission levels for family, friends, or service providers.
Long–Lasting Power & Emergency Backup
Built–in 10,000 mAh battery provides up to 240 days of continuous operation on a single charge.
Low–battery alerts via on–device LED and app notifications, plus a USB–C emergency power port for on–the–spot charging.
Seamless Smart–Home Integration
Control, monitor, and customize access from the TCL Home Security App with real–time notifications and activity history.
Works with Amazon Alexa and Google Assistant for hands–free voice unlocking and scenario automation.
D2 Series at a Glance
Model | Authentication Methods | Highlights | Price (USD) |
D2 Pro | Palm Vein Recognition | 0.3 s unlock • Local storage • 240 days battery • Guest codes | $169.99 |
D2 Plus | AI–Enhanced Fingerprint, PIN, FOB | 0.3 s fingerprint • App control • Encrypted local storage | $119.99 |
D2 | PIN, Physical Key, Mobile App | Remote unlock • Built–in doorbell • Live alerts • Voice control | $79.99 |
Model
Authentication Methods
Highlights
Price (USD)
D2 Pro
Palm Vein Recognition
0.3 s unlock • Local storage • 240 days battery • Guest codes
$169.99
D2 Plus
AI–Enhanced Fingerprint, PIN, FOB
0.3 s fingerprint • App control • Encrypted local storage
$119.99
D2
PIN, Physical Key, Mobile App
Remote unlock • Built–in doorbell • Live alerts • Voice control
$79.99
Availability & Purchase
The TCL D2 Series is available now on TCL's official website and Amazon:
Official Site: https://tclhomesecurity.com
Amazon Store: https://www.amazon.com/dp/B0F89VH168
About TCL
With over four decades of innovation, TCL is a global leader in intelligent technology, offering a broad portfolio across smart–home, entertainment, and mobile categories. Committed to enhancing everyday life, TCL delivers cutting–edge products that blend convenience, security, and style.
Media Contact
Will Bright
Email: will.bright@tcl.com
 
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TCL Unveils D2 Pro Palm Vein Smart Lock with 0.3-Second Unlocking--Open 'Like Iron Man' to Redefine Home Security
SYDNEY, Dec. 16, 2025 /PRNewswire/ -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening.
Commissioned by the Thoracic Research Centre at the University of Queensland and developed in partnership with Queensland Health, Screen2Quit is a revised, clinical version of the My QuitBuddy application redeveloped and instrumented to collect participant backend data for a multi-year randomised controlled trial (RCT). The goal: to determine whether app-based interventions can significantly outperform websites or control conditions in helping people quit smoking, still the leading cause of preventable disease worldwide.
From the outside, Screen2Quit looks and feels familiar to a smoking cessation application, but beneath the surface lies a purpose-built digital trial engine capable of tracking every interaction, from user-entered quit plans through scrolling and page navigation to community engagement, all while maintaining strict research integrity.
MPF's scope included native app development for both iOS and Android, and the creation of two secure backends. One backend supports community forum moderation, while the bespoke administration portal captures trial-specific analytics and fully anonymised data capture. Each app user is registered via a unique trial ID that gates access and ties in-session behaviour to anonymised clinical outcomes, enabling researchers to explore how digital behaviours relate to real-world smoking cessation.
"We're proud to help deliver a real-world health intervention that's not only scalable, but scientifically robust," said Jennifer Wilson, Founder and Futurist MPF. "Screen2Quit takes behaviour change out of the lab and into people's lives—with real data to back it."
The build was delivered in two structured phases:
- Phase 1 focused on core functionality: onboarding updates for trial enrollment, user navigation improvements, analytics configuration, regional localisation, and the creation of a trial-specific forum with moderator tools.
- Phase 2 added deeper analytics, forum download features, enhanced user activity logging, and infrastructure support for multi-jurisdiction deployment.
The app is deployed as part of the ILST (International Lung Screen Trial), which is funded by the NHMRC and supported by a cross-disciplinary clinical team. MPF continues to support the platform under a multi-year maintenance agreement, providing technical oversight, app store management, and hosting infrastructure for the duration of the trial.
About Screen2Quit (MQB UniQLD)
Screen2Quit is a clinical trial app developed for the International Lung Screen Trial, a multi-jurisdiction randomised controlled study coordinated by the University of Queensland Thoracic Research Centre. Based on the evidence-based My QuitBuddy app, Screen2Quit was redeveloped for use in clinical research, enabling detailed tracking of user behaviour and its relationship to smoking cessation outcomes. The app is only available to enrolled trial participants.
About Miroma Project Factory (MPF)
MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across app, web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, visit www.theprojectfactory.com.
For media enquiries, interviews or partnership opportunities, please contact:
Miroma Project Factory
info@theprojectfactory.com
Henry Marshall
Thoracic Research Centre The University of Queensland
quit.research@health.qld.gov.au
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials
Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials
